Key Takeaways:
Healthpeak Properties shares surged 28% in three months as the healthcare real estate investment trust's pivot toward lab and outpatient medical assets gained traction with investors.
"The company's focus on high-barrier markets and its Janus Living platform are creating a clearer growth trajectory," said Kevin Brown, equity analyst at Morningstar.
During the first quarter, Healthpeak executed 141,000 square feet of lab leases — 92% tied to new leasing — and had roughly 355,000 square feet under letter of intent. Lab occupancy reached 77.7%, up from 77% at the end of 2025. The outpatient medical segment delivered nearly 1.1 million square feet of leasing, with cash re-leasing spreads of 5.4% on renewals and 91% total occupancy. Tenant retention stood at 79%. Senior housing same-store cash net operating income rose 13.8% year over year, while Janus Living posted revenue growth of 35% and adjusted EBITDA expansion of 42%.
The company generated $267 million in proceeds from recapitalizations, dispositions and loan repayments in the first quarter, strengthening its liquidity position. Cash and cash equivalents climbed to $1.17 billion from $467.5 million in the prior quarter, driven largely by proceeds from the Janus Living initial public offering. Healthpeak also added a new $400 million unsecured delayed-draw term loan to increase financial flexibility. Its net debt-to-EBITDA stood at 5.4 times, with long-term credit ratings of Baa1 from Moody's and BBB+ from S&P Global.
Lab and Outpatient Momentum
Healthpeak's lab portfolio, concentrated in San Diego, San Francisco and Boston, benefits from sustained investment in drug discovery and development. Management expects year-end 2026 lab occupancy to exceed 2025 levels, supported by the pipeline of leases under letter of intent. The outpatient medical segment maintained solid fundamentals, with additional leasing activity executed after quarter-end through early May and a larger pipeline under letter of intent, which should help sustain occupancy and rent growth.
The stock's 28% gain over the past three months compares with a 12.4% rise for the broader healthcare real estate industry, according to Zacks data. The outperformance reflects investor confidence in Healthpeak's portfolio repositioning toward labs, outpatient medical facilities and life-plan properties in high-barrier-to-entry markets.
What's at Stake
The rally positions Healthpeak to attract further institutional investment into healthcare real estate, particularly as the company demonstrates that its shift toward lab and outpatient assets can generate consistent cash flow. The Janus Living IPO provided a clearer vehicle for senior housing growth, and the company's use of dispositions and structured transactions to fund expansion maintains investment flexibility across cycles. Investors will watch whether Healthpeak can sustain its leasing momentum through the remainder of 2026 and convert its letter-of-intent pipeline into signed leases.
This article is for informational purposes only and does not constitute investment advice.
